AQILION AB

AQILION AB

Description

R&D
extracting and processing pollen to develop and deliver herbal pharmaceutical solutions, improving everyday life for many people.

AQILION AB

Address

Henckels Torg 3, 25220 Helsingborg
Helsingborg, Sweden

Contact

info@aqilion.com / sarah.fredriksson@aqilion.com

Description

R&D
extracting and processing pollen to develop and deliver herbal pharmaceutical solutions, improving everyday life for many people.

Matchmaking

Connect with AQILION AB

This entity is yours?

Update information

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

TRL

AQILION AB last news

10/06/2024

Resolutions from AQILION AB (publ) Annual General Meeting 2024

Helsingborg, June 10, 2024 - AQILION AB (publ) held its Annual General Meeting today, at which the meeting decided in accordance with the proposals presented. For more detailed information on the content of the resolutions, please see the full notice to the Annual General Meeting, which is available on Aqilion's website, www.aqilion.com Adoption of income statements and balance sheets The Annual General Meeting approved the income statement and balance sheet included in the annual report for the business year 2023. The Annual General Meeting decided that the entire amount at the disposal of

21/05/2024

Aqilion to present results at scientific events

[...] AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The presentations will cover the pipeline programs AQ280 for the treatment of eosinophilic esophagitis and AQ312 for the treatmen [...]

17/05/2024

Aqilion to present results at scientific events

AQILION AB (publ) will present updates on the Company's progress and scientific results at two different scientific conferences in May. The presentations will cover the pipeline programs AQ280 for the treatment of eosinophilic esophagitis and AQ312 for the treatment of ulcerative colitis. Johan Lund, CSO, will present Aqilion's pipeline with a special focus on the pipeline programs AQ280 and AQ312 at the 20th Annual Conference of International Drug Discovery and Science technology (IDDST) in Osaka, Japan, May 22-24, (https://www.iddst.com/iddst2024/default.asp ).   Anneli Tinnerholm,